Abstract
Using microinjection of recombinant protein to directly control ‘expression’ levels, we have compared the proliferative response to ras oncogene activation in two normal cell types – fibroblast and thyroid epithelial cell – which give rise to human tumours with very low and high frequencies of ras mutation respectively. A concentration-dependent stimulation of DNA synthesis was observed in thyrocytes, matched by an almost perfectly reciprocal inhibition in fibroblasts. A concentration-dependent induction of the cyclin-dependent kinase (CDK) inhibitor p21WAF1 was observed in both cell types, but p16Ink4a was induced by ras only in fibroblasts. This difference could not account for the fibroblast specificity of the growth-inhibitory response, however, since proliferation of p16-deficient fibroblasts was also inhibited by mutant ras. We conclude that the striking contrast in proliferative response to ras between fibroblasts and thyroid epithelial cells cannot readily be explained by differential induction of either of the two key CDK inhibitors, p16Ink4a and p21WAF1, but is consistent with a differential ability of p21WAF1 to antagonize ras-induced mitogenic signals in the two cell types. Such tissue-specific differences provide an attractive explanation for the observed specificity of ras mutation for particular human tumour types, and emphasize the inappropriateness of fibroblasts as a model for ras-induced tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M . (1988). Cell, 53, 549–554.
Bond JA, Wyllie FS, Rowson J, Radulescu A and Wynford-Thomas D . (1994). Oncogene, 9, 281–290.
Bos JL . (1989). Cancer Res., 49, 4682–4689.
Bredel M and Pollack IF . (1999). Brain Res. Rev., 29, 232–249.
Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W and Peters G . (2002). EMBO J., 21, 2936–2945.
Campbell C, Quinn AG and Rees JL . (1993). Br. J. Dermatol., 128, 111–114.
Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC and Weinberg RA . (2001). Genes Dev., 15, 50–65.
Gire V and Wynford-Thomas D . (1998). Mol. Cell Biol., 18, 1611–1621.
Gire V, Marshall CJ and Wynford-Thomas D . (1999). Oncogene, 18, 4819–4832.
Gruis NA, van der Velden PA, Sandkuijl KA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR . (1995). Nat. Genet., 10, 351–353.
Hahn WC and Weinberg RA . (2002). Nat. Rev. Cancer, 2, 331–341.
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW and Weinberg RA . (1999). Nature, 400, 464–468.
Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J, Bounacer A, Wyllie FS, Ivan M, Bartek J, Wynford-Thomas D and Bond JA . (2000). Mol. Cell. Biol., 20, 5690–5699.
Lazarov M, Kubo Y, Cai T, Dajee M, Tarutani M, Lin Q, Fang M, Tao S, Green CL and Khavari PA . (2002). Nat. Med., 8, 1105–1114.
Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B and Wynford-Thomas D . (1989). Oncogene, 4, 159–164.
Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF and Counter CM . (2001). Cancer Res., 61, 3556–3560.
Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM and Dimmeler S . (2001). Mol. Cell. Biol., 21, 5644–5657.
Schmitt CA . (2003). Nat. Rev. Cancer, 3, 286–295.
Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW . (1997). Cell, 88, 593–602.
Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C and Monier R . (1990). Oncogene, 5, 565–570.
von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE and Boss GR . (2000). Breast Cancer Res. Treat., 62, 51–62.
Wei W, Hemmer RM and Sedivy JM . (2001). Mol. Cell. Biol., 21, 6748–6757.
Wei W, Jobling WA, Chen W, Hahn WC and Sedivy JM . (2003). Mol. Cell. Biol., 23, 2859–2870.
Williams DW, Williams ED and Wynford-Thomas D . (1988). Br. J. Cancer, 57, 535–539.
Woods D, Parry D, Cherwinski H, Bosch E, Lees E and McMahon M . (1997). Mol. Cell. Biol., 17, 5598–5611.
Zhu Y and Parada LF . (2002). Nat. Rev. Cancer, 2, 616–626.
Acknowledgements
We are grateful to Dr Gordon Peters (CR-UK London Research Institute) for supply of the ‘Leiden’ p16-deficient fibroblast strain, and to Dr James Smith (Houston) for the HCA2 fibroblast strain. We thank Cancer Research UK for grant support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Skinner, J., Bounacer, A., Bond, J. et al. Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis. Oncogene 23, 5994–5999 (2004). https://doi.org/10.1038/sj.onc.1207798
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207798
Keywords
This article is cited by
-
Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models
Oncogene (2014)
-
Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells
Breast Cancer Research (2012)
-
Cellular senescence: when bad things happen to good cells
Nature Reviews Molecular Cell Biology (2007)
-
Mutations in PIK3CAare infrequent in neuroblastoma
BMC Cancer (2006)